Seres Therapeutics, Inc. has started a rolling biologics license application with the US FDA for SER-109 in recurrent Clostridium difficile infection (CDI) with a mid-year completion date in what could be a tipping point for microbiome therapeutics.
Following the success of the pivotal ECOSPOR III trial, the US Food and Drug Administration had asked the firm to submit SER-109 safety data from at least 300 subjects which...